Skip to main content

BRIEF RESEARCH REPORT article

Front. Neurol.
Sec. Neurogenetics
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1455467
This article is part of the Research Topic Genetics in Rare Neurological Diseases: From Discovery to Targeted Treatment View all 7 articles

Genetic profile of progressive myoclonic epilepsy in Mali reveals novel findings

Provisionally accepted
  • 1 Faculté de Médecine et d'Odontostomatologie, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali
  • 2 Service de Médecine Générale, Hôpital Nianankoro Fomba de Ségou, Ségou, Mali
  • 3 Pediatric Genomics Discovery Program (PGDP), Yale School of Medicine, New Haven, CT, United States
  • 4 Service de Neurologie, Centre Hospitalier Universitaire Gabriel Touré, Bamako, Mali
  • 5 McKusick-Nathans Institute of Genetic Medicine, School of Medicine, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • 6 Service de Neurologie, Centre Hospitalier Universitaire du Point G, Bamako, Mali
  • 7 Clinique médicale Dinandougou, Markacoungo, Mali
  • 8 Service de Pédiatrie, Centre Hospitalier Universitaire Gabriel Touré, Bamako, Mali
  • 9 Neurogenetics Branch, NINDS, NIH, Bethesda, MD, United States

The final, formatted version of the article will be published soon.

    Progressive myoclonic epilepsy (PME) is a group of neurological disorders characterized by recurrent myoclonic seizures with progressive neurological deterioration. We investigated the genetics of three unrelated patients patients with PME from Mali, a country in sub-Saharan Africa highly underrepresented in genetic and genomic research.Participants were carefully examined and phenotyped. DNA was obtained for genetic analysis including whole exome sequencing (WES). In silico prediction tools and ACMG criteria were used to assess the deleteriousness of putative candidate variants.Pedigree analysis suggests autosomal recessive inheritance patterns for one family and sporadic forms of PME for the two other cases. WES identified novel homozygous missense variants in all the three patients, one each for NHLRC1, EPM2A, and NEU1. The sequence variants segregated with PME in each family and in silico studies including protein 3D structures, CADD scores and ACMG criteria suggested that they were damaging.PME is a group of clinically heterogeneous neurological disorders. Most reported cases in the literature are from European background with only a few cases described in North Africa. We report here novel pathogenic variants in three different genes causing PME phenotypes in three unrelated Malian patients, suggesting that genetic studies of underrepresented populations may expand the genetic epidemiology of PME. These findings also emphasize the need for inclusive genetic research to ensure a more targeted diagnostic and therapeutic approaches for diverse patient populations.

    Keywords: Progressive myoclonic epilepsy, Novel variants, Mali, West Africa, genetic

    Received: 26 Jun 2024; Accepted: 13 Aug 2024.

    Copyright: © 2024 Cissé, Bamba, Diallo, Ji, Dembélé, Yalcouyé, Coulibaly, Traoré, Jeffries, Diarra, Maiga, Diallo, Nimaga, Touré, Traoré, Kotioumbé, Mis, Cissé, Guinto, Fischbeck, Khokha, Lakhani and Landouré. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lassana Cissé, Faculté de Médecine et d'Odontostomatologie, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.